ImmunityBio, Inc.
ImmunityBio Announces $75 Million Equity Financing
Summary
On April 7, 2025, ImmunityBio, Inc. entered into a securities purchase agreement for a registered direct offering with an institutional investor, raising approximately $75 million in gross proceeds. The offering includes the issuance of 29,024,768 shares of common stock and warrants to purchase an additional 29,024,768 shares at an exercise price of $3.101 per share. The closing is expected on or about April 9, 2025, subject to customary closing conditions. The securities are offered under a shelf registration statement on Form S-3. On April 8, 2025, the Company issued a press release announcing the offering under Regulation FD. Legal opinion on the offering is provided by Wilson Sonsini Goodrich & Rosati, P.C., and the offering is subject to certain risks detailed in the Company's SEC filings.
Profitelligence Alerts
Get alerts for IBRX
Be first to know when ImmunityBio, Inc. files with the SEC.
Filing Categories
Exhibits (4)
Advertisement
About ImmunityBio, Inc.
ImmunityBio, Inc. is a pioneering biotechnology company that focuses on developing innovative immunotherapies to treat cancer and other serious diseases. The company's primary function is to leverage the body's immune system to fight against various forms of cancer as well as infectious diseases through a robust pipeline of therapies. ImmunityBio's notable features include its expansive portfolio of next-generation therapies that incorporate cutting-edge technologies, such as the NANT Cancer Vaccine and Anktiva, which are designed to enhance the immune system's natural ability to identify and eradicate tumor cells. The company plays a critical role in the healthcare and biotechnology sectors, contributing to advancements in personalized medicine and potentially transformative treatments. Headquartered in California, ImmunityBio is strategically placed in the biotechnology hub of the United States, allowing it to effectively collaborate with key players in research and clinical development. Its work is significant in the market as it represents the ongoing shift towards immunotherapy as a front-line treatment for cancer, promising to impact patient outcomes and the future of cancer care.
Official SEC Documents
Advertisement